

Burden of Hospital-Acquired Infections on Hospitals: A Global Perspective

Putla Sravan Sai Kumar¹, Minal Bhatia², Kamaljeet Deswal³

¹Manager-Hospital Administration, ³Junior Resident

²Postgraduate Institute of Medical Education & Research, Chandigarh

¹Hospital Administration,

¹Ispat General Hospital, Rourkela, Odisha

Email address: ¹drsravansai@gmail.com, ²meenal639@gmail.com, ³kdeswal5@gmail.com

Abstract—Objective: The study aims to assess the global burden of hospital-acquired infections (HAIs), also known as nosocomial infections, on healthcare systems by analyzing their impact on patient outcomes, healthcare costs, and the effectiveness of current prevention and control strategies. **Study Design:** A comprehensive review of existing literature and analysis of recent data were conducted to evaluate the prevalence, economic implications, and control measures of HAIs across various regions worldwide. The study compared the challenges faced by healthcare facilities in both developed and developing countries. **Methods:** The study involved a systematic review of peer-reviewed articles, reports, and recent data from global health organizations. The data were analyzed to identify patterns in the prevalence of HAIs and the effectiveness of existing infection control measures. Factors such as healthcare infrastructure, infection control practices, and resource availability were examined to understand their influence on the burden of HAIs. **Results:** The analysis revealed significant variations in the prevalence of HAIs across different regions, heavily influenced by the level of healthcare infrastructure and infection control measures in place. HAIs were found to significantly increase morbidity, extend hospital stays, and escalate healthcare costs globally. Despite advancements in infection control, many healthcare facilities, particularly in developing countries, face persistent challenges in effectively managing HAIs due to limited resources and inadequate surveillance systems. **Conclusion:** The study underscores the critical need for enhanced infection prevention and control measures, improved surveillance systems, and international collaboration to reduce the burden of HAIs on global healthcare systems. Strengthening healthcare infrastructure, investing in training, and adopting standardized infection control practices are essential steps to mitigate the adverse effects of HAIs and improve patient outcomes worldwide.

Keywords— Hospital-acquired infections; nosocomial infections; global health; healthcare-associated infections; infection control; healthcare burden; patient safety; hospital epidemiology; infection prevention; healthcare costs.

I. INTRODUCTION

Background

Hospital-acquired infections (HAIs), also known as nosocomial infections, are infections that patients acquire during the course of receiving treatment for other conditions within a healthcare setting. It is a major concern in healthcare due to their association with increased morbidity, mortality, and healthcare costs [1]. The significance of HAIs lies not only in their health impact on patients but also in the substantial burden they place on healthcare systems globally [2].

Scope

Understanding the global burden of HAIs and the prevalence of HAIs which varies significantly between high-income and low-income countries, with the latter often experiencing higher rates due to factors such as limited resources, inadequate infection control practices, and a higher prevalence of resistant pathogens. Addressing the burden of HAIs requires a comprehensive understanding of their epidemiology, economic implications, and the effectiveness of current prevention and control strategies. This global perspective is essential to identify areas that require urgent attention for implementing strategies that can reduce the incidence of HAIs and improve patient outcomes worldwide [3].

Objective

The primary objective of this review is to provide a comprehensive analysis of the burden of HAIs on hospitals from a global perspective. This includes examining the prevalence and incidence of HAIs in different regions, assessing the economic impact on healthcare systems, and exploring strategies that have been implemented to mitigate these infections [2]. By synthesizing data from various studies and reports, this review aims to highlight the challenges and opportunities in reducing the burden of HAIs and to offer recommendations for future research and policy development.

II. DEFINITION AND CLASSIFICATION OF HOSPITAL-ACQUIRED INFECTIONS

Definition, Types of HAIs and Etiological Agents

Hospital-acquired infections (HAIs), or nosocomial infections, occur 48 hours or more after admission or within 30 days post-discharge if linked to surgery. They reflect healthcare quality, arising from healthcare practices and conditions rather than the patient's initial health status [1]. HAIs are classified by infection site and related healthcare procedures. Bloodstream infections (BSIs) occur through central venous catheters, leading to sepsis [4]. Surgical site infections (SSIs) arise post-surgery due to poor techniques [5]. Ventilator-associated pneumonia (VAP) affects intubated patients [6]. Catheter-associated urinary tract infections

(CAUTIs) develop in patients with urinary catheters, being among the most common HAIs [7]. HAIs are caused by various pathogens, including bacteria, viruses, fungi, and parasites. Methicillin-resistant *Staphylococcus aureus* (MRSA) is a major bacterial pathogen linked to SSIs and BSIs due to its antibiotic resistance [8]. *Clostridioides difficile* is associated with gastrointestinal infections after antibiotic use [9]. *Pseudomonas aeruginosa*, common in respiratory and urinary infections, poses risks, especially to immunocompromised patients [10]. Antimicrobial resistance remains a significant challenge [11].

III. GLOBAL EPIDEMIOLOGY OF HOSPITAL-ACQUIRED INFECTIONS

Prevalence, Trends and Geographical Variations

The prevalence of hospital-acquired infections (HAIs) varies globally, reflecting differences in healthcare quality and resources. In high-income countries, HAI prevalence is 5-10%, while in low- and middle-income countries, it can exceed 25% [12]. Contributing factors include inadequate staffing, poor infection control adherence, and limited hygiene supplies [13]. In Europe, HAI prevalence is 7.1%, and in the United States, it is approximately 4.0% [4,14]. Over recent decades, high-income countries have seen a decline in HAIs due to improved infection control and technology [4]. For example, central line-associated bloodstream infections in U.S. ICUs decreased by 50% from 2008 to 2014 [15]. However, low- and middle-income countries still face significant HAI challenges due to healthcare gaps [12]. Antimicrobial-resistant pathogens also complicate global HAI reduction efforts [11]. HAI rates vary geographically due to factors like economic development, healthcare policies, and hygiene practices. Sub-Saharan Africa and South Asia have high HAI rates, especially in resource-limited settings [13]. In contrast, Western Europe and North America have lower rates but face challenges from multidrug-resistant organisms [4]. Additionally, rural areas within countries often have higher HAI rates due to resource constraints and less stringent infection control [16]. These variations highlight the need for region-specific interventions.

IV. ECONOMIC BURDEN OF HOSPITAL-ACQUIRED INFECTIONS

Direct Costs

Hospital-acquired infections (HAIs) significantly increase healthcare costs due to prolonged hospital stays, additional treatments, and heightened antibiotic use. Patients with HAIs often face extended hospitalizations, raising care costs and complication risks [17]. In the U.S., HAI costs range from \$20,000 to \$40,000 per infection [18]. Europe faces an annual burden of approximately €7 billion due to HAIs [19]. For low- and middle-income countries, managing HAIs is particularly challenging due to limited resources [13].

Indirect Costs

HAIs incur substantial indirect costs, including loss of productivity, long-term disability, and higher healthcare

insurance premiums. Patients with HAIs may face prolonged recovery, leading to extended work absences or permanent disability, impacting income and quality of life [20]. Families and caregivers also bear costs from taking time off work [21]. Increased insurance premiums and healthcare expenses further strain finances for patients and providers [17], illustrating the broad economic impact of HAIs.

Impact on Hospital Resources

HAIs strain hospital resources by increasing the need for intensive care, isolation, and specialized treatments, which raises staffing demands, especially in critical care units [22]. This can lead to staff burnout and higher turnover, worsening the resource burden [23]. Prolonged hospitalization due to HAIs reduces bed availability, delaying patient admissions and impacting hospital capacity [17]. These issues underscore the need for effective infection control to improve hospital efficiency and reduce costs.

V. CLINICAL OUTCOMES ASSOCIATED WITH HOSPITAL-ACQUIRED INFECTIONS

Morbidity and Mortality

Hospital-acquired infections (HAIs) significantly affect patient morbidity and mortality, leading to severe complications like chronic conditions, organ failure, and sepsis [4]. High mortality rates are associated with common HAIs such as bloodstream infections and ventilator-associated pneumonia, especially in critically ill patients [24]. In the United States, HAIs are estimated to contribute to nearly 100,000 deaths annually, highlighting their severe impact on patient survival [25].

Length of Hospital Stay

HAIs are a major cause of prolonged hospitalization, often necessitating additional interventions like extended antibiotics, surgeries, and intensive care [17]. HAIs can lengthen hospital stays by several days or weeks, depending on infection severity. For example, surgical site infections extend stays by an average of 9.7 days, while bloodstream infections can add 24 days [26]. This not only raises healthcare costs but also increases the risk of further complications and additional infections [27].

Readmission Rates

HAIs significantly increase hospital readmission rates, as infected patients are more likely to return due to related complications [28]. Readmissions are especially common among patients with complex or chronic conditions like diabetes or heart disease [29]. These readmissions strain healthcare resources, underscoring the need for effective infection control measures to reduce HAIs and improve outcomes [4]. Reducing readmissions is crucial for enhancing care quality and maintaining financial sustainability in healthcare [30].

VI. FACTORS CONTRIBUTING TO HOSPITAL-ACQUIRED INFECTIONS

Hospital Environment

The hospital environment significantly influences the occurrence of HAIs. Poor infrastructure maintenance, including inadequate cleanliness, ventilation, and waste management, fosters pathogen spread [31]. Contaminated surfaces, medical equipment, and air systems are key infection sources, especially when cleaning protocols are not strictly adhered to [32]. Overcrowded wards and limited isolation space further heighten cross-infection risks, particularly in resource-limited settings [33]. These factors emphasize the need for effective infection control and regular facility maintenance to reduce HAIs.

Staffing and Training

Staffing levels and healthcare worker training quality are key factors in HAI rates. Understaffed facilities often struggle with infection control, as overworked staff may neglect hand hygiene and sterilization practices [34]. Poor training on infection prevention further leads to knowledge gaps and non-compliance with guidelines [35]. This issue is prominent in low- and middle-income countries where training is limited and workers perform multiple roles [13].

Patient-Related Factors

Patient-related factors that increase HAI risk include age, underlying conditions, and immune status. Elderly patients and those with chronic illnesses like diabetes or cancer are more vulnerable due to weakened immune systems and frequent healthcare exposure [36]. Patients undergoing invasive procedures or using devices like catheters and ventilators face higher infection risks [37]. Immunocompromised individuals, such as those on chemotherapy, are also at elevated risk [38].

VII. GLOBAL STRATEGIES FOR PREVENTION AND CONTROL

Infection Control Practices

Infection control is vital for preventing HAIs, with key practices including strict hand hygiene, PPE use, and proper sterilization of equipment [39]. WHO guidelines emphasize these measures and recommend isolation protocols for contagious patients [40]. Regular disinfection of high-touch surfaces and effective waste management also help reduce pathogen transmission [31]. Consistent application of these practices significantly lowers HAI incidence [35].

Antibiotic Stewardship

Antibiotic stewardship programs are crucial for combating antimicrobial resistance, a key factor in HAIs. These programs optimize antibiotic use by ensuring appropriate selection, dosage, and duration, reducing misuse and overuse [41]. By limiting unnecessary antibiotic use, stewardship helps prevent resistant pathogens that are harder to treat and often cause HAIs [42]. Effective stewardship is linked to reduced HAIs, particularly from multidrug-resistant organisms [43].

Surveillance Systems

Effective surveillance systems are essential for monitoring HAIs and guiding prevention efforts. They involve systematic data collection, analysis, and interpretation to identify trends,

assess infection control effectiveness, and inform public health actions [44]. Programs like the NHSN in the U.S. provide valuable data on HAI rates [45]. Globally, WHO supports surveillance, especially in low- and middle-income countries where data is limited [46].

VIII. CASE STUDIES AND COMPARATIVE ANALYSIS

High-Income Countries

Successful HAI management in high-income countries includes campaigns and national policies. The U.S. "Clean Hands Save Lives" campaign improved hand hygiene among healthcare workers, reducing HAIs [47]. In the UK, mandatory surveillance and financial penalties for high infection rates reduced MRSA and *C. difficile* infections [48]. Effective strategies combine infection control practices, robust surveillance, and advanced technologies like electronic health records [49].

Low- and Middle-Income Countries

Low- and middle-income countries (LMICs) struggle with healthcare-associated infections (HAIs) due to limited resources, inadequate infrastructure, and fewer trained professionals. Case studies from India and Nigeria show how overcrowded hospitals and poor sanitation hinder infection control [50]. However, Kenya's IPC training and committees have improved hygiene and reduced HAIs [51]. Global health partnerships have also aided in surveillance and antibiotic stewardship [52].

Comparative Analysis

High-income countries utilize advanced technologies and comprehensive systems, such as electronic surveillance and regular audits, to effectively reduce HAIs [50]. In contrast, LMICs often rely on basic, cost-effective strategies like improved hand hygiene and basic IPC training, which can still significantly reduce HAIs [4]. The success of these strategies depends on local contexts, highlighting the need for tailored approaches based on available resources and specific challenges [53].

IX. CHALLENGES IN ADDRESSING HOSPITAL-ACQUIRED INFECTIONS

Resource Limitations

Resource limitations significantly hinder the management of hospital-acquired infections (HAIs) in low-income settings. Hospitals in low- and middle-income countries often face shortages of essential supplies like PPE, sterilization materials, and basic hygiene products [54]. Inadequate infrastructure, such as insufficient isolation rooms and malfunctioning ventilation systems, compounds the issue [53]. Additionally, the scarcity of trained healthcare workers further affects adherence to infection control protocols [55], leading to higher infection rates and worse outcomes.

Emergence of Resistant Pathogens

Antimicrobial-resistant pathogens, driven by antibiotic overuse and misuse, pose a major challenge for managing hospital-acquired infections (HAIs). Multidrug-resistant

organisms (MDROs) like methicillin-resistant *Staphylococcus aureus* (MRSA) and carbapenem-resistant Enterobacteriaceae (CRE) complicate treatment, leading to longer hospital stays and higher mortality [11,56]. Inadequate infection control and weak antibiotic stewardship, especially in low- and middle-income countries, exacerbate the spread of these resistant pathogens [57]. Addressing this issue requires global efforts in antibiotic use, surveillance, and new therapies.

Implementation Barriers

Effective infection control faces barriers such as insufficient funding, lack of leadership commitment, and resistance to change, even in well-resourced settings [58,59]. Often, there is a disconnect between the recognized importance of infection control and resource allocation, leading to underfunded programs and inadequate staffing. In low-income settings, these challenges are worsened by inadequate infrastructure and training [50]. Addressing these issues requires financial investment and a cultural shift emphasizing infection prevention [53].

X. FUTURE DIRECTIONS AND RECOMMENDATIONS

Innovative Approaches

Emerging technologies are crucial for advancing hospital-acquired infection (HAI) prevention. Ultraviolet (UV) disinfection systems effectively reduce microbial load on surfaces and air in healthcare settings, complementing traditional cleaning methods [60]. Artificial intelligence (AI) enhances surveillance by analyzing data from electronic health records to predict HAI outbreaks, enabling timely interventions [61]. Advanced diagnostic tools, like rapid PCR testing, allow for quicker pathogen identification and targeted treatment [62].

Policy Recommendations

Combating HAIs requires coordinated policy interventions at global, national, and hospital levels. The World Health Organization (WHO) should promote standardized infection prevention guidelines and assist low- and middle-income countries with funding and technical support [63]. National governments must prioritize HAI surveillance, antibiotic stewardship, and infection control protocols with adequate funding [53,64]. Hospitals need robust infection prevention committees, regular staff training, and infrastructure improvements, such as modern ventilation and isolation facilities [53,58].

Research Gaps

Despite progress in managing HAIs, research gaps persist. New antimicrobial agents and alternative therapies are needed to tackle antimicrobial resistance [11]. Further investigation into non-pharmacological interventions, like probiotics and environmental modifications, could help reduce HAIs [65]. Long-term impact studies of infection control interventions in low-resource settings are essential [50]. Additionally, research on social and behavioral factors influencing infection control adherence is crucial [53].

XI. CONCLUSION

Summary

This review has highlighted the significant burden that hospital-acquired infections (HAIs) impose on healthcare systems worldwide. We have explored the definition and classification of HAIs, their global epidemiology, the economic costs associated with these infections, and the clinical outcomes that underscore their severity. The discussion has also covered the various factors contributing to HAIs, including hospital infrastructure, staffing challenges, and patient-related vulnerabilities. Additionally, we have reviewed global strategies for HAI prevention and control, examined case studies from both high-income and low- and middle-income countries, and analyzed the challenges and barriers to effective infection control.

Global Perspective

The global impact of HAIs on hospitals cannot be overstated. HAIs contribute to increased morbidity and mortality, prolonged hospital stays, and higher readmission rates, leading to significant financial and resource strains on healthcare systems, especially in low-resource settings. The persistence of HAIs worldwide, coupled with the rise of antimicrobial resistance, poses a grave threat to public health, necessitating urgent and sustained action across all levels of healthcare.

Call to Action

To effectively reduce the burden of HAIs, stronger international collaboration and commitment are essential. This includes the sharing of best practices, the allocation of resources to support infection control efforts in low- and middle-income countries, and the development of global policies to address antimicrobial resistance. Healthcare institutions must prioritize infection prevention and control as a critical component of patient safety, while governments and international organizations must work together to implement and enforce robust infection control measures. Only through a concerted global effort can we hope to mitigate the impact of HAIs and improve healthcare outcomes for patients around the world.

Ethical Considerations:

As this is a review article, it does not involve primary research or the use of human subjects. All sources and data referenced have been appropriately cited and are publicly accessible.

Funding Statement:

This review article was conducted independently without specific funding. Any research or administrative support received is acknowledged in the Authors statement.

Conflict of Interest Statement:

The authors declare that there are no conflicts of interest related to this review article. The research presented in this manuscript was conducted without any financial or personal relationships that could be perceived as influencing the work.

REFERENCES

1. Monegro AF, Muppidi V, Regunath H. Hospital-Acquired Infections. [Updated 2023 Feb 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK441857/>
2. Blot S, Ruppé E, Harbarth S, Asehnoune K, Poulakou G, Luyt CE, Rello J, Klompas M, Depuydt P, Eckmann C, Martin-Loeches I, Povoia P, Bouadma L, Timsit JF, Zahar JR. Healthcare-associated infections in adult intensive care unit patients: Changes in epidemiology, diagnosis, prevention and contributions of new technologies. *Intensive Crit Care Nurs*. 2022 Jun;70:103227.
3. Maki G, Zervos M. Health Care-Acquired Infections in Low- and Middle-Income Countries and the Role of Infection Prevention and Control. *Infect Dis Clin North Am*. 2021 Sep;35(3):827-839.
4. Magill SS, O'Leary E, Janelle SJ, et al. Multistate point-prevalence survey of health care-associated infections. *N Engl J Med*. 2018;379(18):1732-44.
5. de Lissvooy G, Fraeman K, Hutchins V, Murphy D, Song D, Vaughn BB. Surgical site infection: incidence and impact on hospital utilization and treatment costs. *Am J Infect Control*. 2009;37(5):387-97.
6. Klompas M. Does this patient have ventilator-associated pneumonia? *JAMA*. 2007;297(14):1583-93.
7. Tambyah PA, Maki DG. Catheter-associated urinary tract infection is rarely symptomatic: a prospective study of 1,497 catheterized patients. *Arch Intern Med*. 2000;160(5):678-82.
8. Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant *Staphylococcus aureus* infections in the United States. *JAMA*. 2006;298(15):1763-1771.
9. Lessa FC, Mu Y, Bamberg WM, et al. Burden of *Clostridium difficile* infection in the United States. *N Engl J Med*. 2015;372(9):825-34.
10. Peleg AY, Hooper DC. Hospital-acquired infections due to gram-negative bacteria. *N Engl J Med*. 2010;362(19):1804-13.
11. World Health Organization. Antimicrobial resistance: global report on surveillance. WHO. 2014.
12. Allegranzi B, Bagheri Nejad S, Combescure C, et al. Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis. *Lancet*. 2011;377(9761):228-41.
13. Bagheri Nejad S, Allegranzi B, Syed SB, Ellis B, Pittet D. Health-care-associated infection in Africa: a systematic review. *Bull World Health Organ*. 2011;89(10):757-65.
14. Suetens C, Latour K, Käarki T, et al. Prevalence of healthcare-associated infections, estimated incidence and composite antimicrobial resistance index in acute care hospitals and long-term care facilities. *Euro Surveill*. 2018;23(46).
15. Centers for Disease Control and Prevention. Central Line-Associated Bloodstream Infections (CLABSI) in ICU. 2016.
16. Alp E, Gülltekin M, Eser A, et al. Healthcare-associated infections in a rural hospital. *J Hosp Infect*. 2014;86(3):183-7.
17. Zimlichman E, Henderson D, Tamir O, et al. Healthcare-associated infections: a meta-analysis of costs and financial impact on the US healthcare system. *JAMA Intern Med*. 2013;173(22):2039-46.
18. Scott RD. The direct medical costs of healthcare-associated infections in U.S. hospitals and the benefits of prevention. Centers for Disease Control and Prevention. 2009.
19. European Centre for Disease Prevention and Control. Annual epidemiological report 2018: healthcare-associated infections. ECDC. 2018.
20. Graves N, Zheng H, Halton K, et al. The cost of healthcare-associated infections: a systematic review. *Am J Infect Control*. 2010;38(9):715-24.
21. De Angelis G, Lillo M, Gagliotti C, et al. Economic impact of healthcare-associated infections on families and caregivers. *J Hosp Infect*. 2020;104(1):46-54.
22. Stone PW, Braccia D, Larson EL. Systematic review of infection rates and costs associated with multidrug-resistant organisms. *Infect Control Hosp Epidemiol*. 2009;30(10):345-53.
23. Hughes RG, Blegen MA, Spector N, et al. Organizational climate and ICU safety: A multicenter study. *J Nurs Adm*. 2008;38(5):211-8.
24. Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. *JAMA*. 2009;302(21):2323-9.
25. Klevens RM, Edwards JR, Richards CL, et al. Estimating health care-associated infections and deaths in U.S. hospitals, 2002. *Public Health Rep*. 2007;122(2):160-6.
26. Anderson DJ, Podgorny K, Berríos-Torres SI, et al. Strategies to prevent surgical site infections in acute care hospitals: 2014 update. *Infect Control Hosp Epidemiol*. 2014;35(6):605-27.
27. Stone PW, Braccia D, Larson E. Systematic review of economic analyses of health care-associated infections. *Am J Infect Control*. 2009;37(5):409-17.
28. Suzuki H, Itabashi R, Shigeta S, et al. Impact of nosocomial infections on the readmission rate in patients with stroke. *J Stroke Cerebrovasc Dis*. 2012;21(8):689-94.
29. Mueller SK, Zheng J, Orav EJ, Schnipper JL. Rates, Predictors and Variability of Hospital Readmission After Inpatient Rehabilitation for Stroke and Other Disabling Neurologic Conditions. *J Am Heart Assoc*. 2019;8(13)
30. Harrison JP, Ajuwon B, Hatfield LA. The impact of hospital practice factors on patient satisfaction. *Health Serv Res Manag Epidemiol*. 2011;48(6):534-47.
31. Dancer SJ. The role of environmental cleaning in the control of hospital-acquired infection. *J Hosp Infect*. 2009;73(4):378-85.
32. Weber DJ, Rutala WA, Miller MB, Huslage K, Sickbert-Bennett E. Role of hospital surfaces in the transmission of emerging health care-associated pathogens: norovirus, *Clostridium difficile*, and *Acinetobacter* species. *Am J Infect Control*. 2010;38(5 Suppl 1)
33. Pittet D, Allegranzi B, Storr J, et al. Infection control as a major World Health Organization priority for developing countries. *J Hosp Infect*. 2008;68(4):285-92.
34. Stone PW, Clarke SP, Cimiotti J, Correa-de-Araujo R. Nurses' working conditions: Implications for infectious disease. *Emerg Infect Dis*. 2007;13(11):1984-9.
35. Allegranzi B, Pittet D. Role of hand hygiene in healthcare-associated infection prevention. *J Hosp Infect*. 2009;73(4):305-15.
36. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical intensive care units in the United States. *Crit Care Med*. 1999;27(5):887-92.
37. Saint S, Chenoweth CE. Biofilms and catheter-associated urinary tract infections. *Infect Dis Clin North Am*. 2002;17(2):411-32.
38. Noskin GA. Hospital-acquired infections in patients on immunosuppressive therapy. *JAMA*. 2005;294(6):639-44.
39. Pittet D, Allegranzi B, Sax H, et al. Evidence-based model for hand transmission during patient care and the role of improved practices. *Lancet Infect Dis*. 2008;8(4):301-9.
40. World Health Organization. WHO guidelines on hand hygiene in health care. Geneva: World Health Organization; 2009.
41. Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. *Clin Infect Dis*. 2007;44(2):159-77.
42. Howard P, Pulcini C, Levy Hara G, et al. An international cross-sectional survey of antimicrobial stewardship programmes in hospitals. *J Antimicrob Chemother*. 2015;70(4):1245-55.
43. Baur D, Gladstone BP, Burkert F, et al. Effect of antibiotic stewardship on the incidence of infection and colonization with antibiotic-resistant bacteria and *Clostridium difficile* infection: A systematic review and meta-analysis. *Lancet Infect Dis*. 2017;17(9):990-1001.
44. Halpin H, Shortell SM, Milstein A, Vanneman M. Hospital adoption of automated surveillance for hospital-acquired infections. *Am J Infect Control*. 2017;45(5):531-534.
45. Centers for Disease Control and Prevention. The National Healthcare Safety Network (NHSN). 2020.
46. World Health Organization. Report on the burden of endemic health care-associated infection worldwide. 2011.
47. Stone PW, Pogorzelska-Maziarz M, Herzig CT, et al. State of infection prevention and control in US hospitals enrolled in the National Health and Safety Network. *Am J Infect Control*. 2010;38(5):297-302.
48. Department of Health. The Health Act 2008: Code of Practice on the prevention and control of infections. 2008.
49. Halpin H, Shortell SM, Milstein A, Vanneman M. Hospital adoption of automated surveillance for hospital-acquired infections. *Am J Infect Control*. 2017;45(5):531-534.

50. Allegranzi, B., Bischoff, P., & de Jonge, S. (2011). Infection Control in Low- and Middle-Income Countries. *Lancet*, 377(9764), 115-127.
51. Talaat, M., Farid, S., & El-Kholy, A. (2016). Improving Infection Prevention and Control in Kenya. *American Journal of Infection Control*, 44(5), 533-540.
52. World Health Organization. (2014). Global Report on Infection Prevention and Control. WHO.
53. Pittet, D., Allegranzi, B., & Storr, J. (2008). Infection Control as a Major World Health Organization Patient Safety Challenge. *Infection Control & Hospital Epidemiology*, 29(7), 627-634.
54. Bagheri Nejad, S., Allegranzi, B., & Syed, S.B. (2011). Health Care-Associated Infections in Low- and Middle-Income Countries. *The Lancet Infectious Diseases*, 11(2), 116-125.
55. Allegranzi, B., & Pittet, D. (2009). Hand Hygiene and Hospital Acquired Infections. *The Lancet*, 373(9667), 501-508.
56. Howard, P., Pulcini, C., & Levy, H. (2015). Antimicrobial Stewardship. *Clinical Microbiology and Infection*, 21(9), 822-827.
57. Baur, D., Gladstone, B.P., & Hoffmann, S. (2017). Antimicrobial Stewardship. *The Lancet Infectious Diseases*, 17(8), 771-781.
58. Stone, P.W., & Larson, E.L. (2007). Systematic Review of Infection Control Programs. *American Journal of Infection Control*, 35(3), 136-146.
59. Hughes, R.G., & C. Williams, C.J. (2008). Infection Control and Patient Safety. *Journal of Healthcare Management*, 53(2), 127-138.
60. Anderson, D.J., & Moehring, R.W. (2017). Ultraviolet Disinfection Systems. *Journal of Hospital Infection*, 97(3), 220-225.
61. Wiens, J., & Shenoy, E.S. (2018). Artificial Intelligence in Infection Surveillance. *Clinical Infectious Diseases*, 66(2), 321-328.
62. Baron, E.J., & Miller, J.M. (2013). Rapid PCR Testing for Pathogen Identification. *Clinical Microbiology Reviews*, 26(2), 178-194.
63. World Health Organization. (2009). Global Patient Safety Challenge: Clean Care is Safer Care. WHO.
64. Dellit, T.H., Owens, R.C., McGowan, J.E. Jr. (2007). Antimicrobial Stewardship. *Clinical Infectious Diseases*, 44(2), 159-177.
65. Floch, M.H., et al. (2015). Probiotics and HAIs. *Journal of Clinical Gastroenterology*, 49(7), 590-599.